Akari Therapeutics Appoints Samir R. Patel As Interim CEO; Plans For Prioritization Of Peak Bio's ADC Cancer Therapeutic Platform Technology And Akari's PAS-Nomacopan For Geographic Atrophy
Akari Therapeutics Appoints Samir R. Patel As Interim CEO; Plans For Prioritization Of Peak Bio's ADC Cancer Therapeutic Platform Technology And Akari's PAS-Nomacopan For Geographic Atrophy
Samir R. Patel, M.D. Appointed Interim CEO; Interim CEO Employment Contract Demonstrates Alignment with Shareholders
Samir R. Patel万.D. 被任命为临时CEO；临时CEO的雇佣合同表明与股东的利益一致。
Plan for Prioritization of Peak Bio's ADC Cancer Therapeutic Platform Technology and Akari's PAS-nomacopan for Geographic Atrophy
制定Peak Bio的ADC癌症治疗平台技术和Akari的PAS-nomacopan在地理萎缩方面的优先安排计划。
Existing Investors Support the Company with Issuance of $1 Million in Unsecured Convertible Notes
现有投资者通过发行价值100万美元的无担保可转换票据支持公司。
Secured $7.6 Million in Upsized Financing Round
通过增加融资轮次获得760万美元的担保资金。
Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy
在处理地理萎缩症方面，接收到美国FDA对PAS-nomacopan的积极和建设性的临床前反馈。
BOSTON and LONDON, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, has reported financial results for the second quarter ended June 30, 2024 as well as recent company highlights.
波士顿和伦敦，2024年8月19日（全球新闻通讯社）-- Akari Therapeutics, Plc（纳斯达克股票代码：AKTX）是一家创新的生物技术公司，致力于开发先进的自身免疫和炎症性疾病治疗方案，并报告了截至2024年6月30日的第二季度财务业绩以及公司最近的亮点。
